Biosimulation Expansion And AI Products Will Drive Long Term Margin Upside

Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls

Published

13 Dec 25

Updated

05 Aug 26

Views

Not Invested

Shared on 05 Aug 26

Fair value Decreased 10%

CERT: Peer Deal Premium And Buybacks Will Highlight Depressed Multiple

A recent deal for a similar company makes Certara’s current market value look out of step, and new leadership is pushing deeper into drug discovery to build a steadier business. With a bigger buyback plan and a new AI partnership in play, the key question is whether these moves can change how investors value the company after a weaker quarter.

0 views

Shared on 02 Jul 26

Fair value Decreased 38%

CERT: Peer Deal Premium Will Highlight Depressed Multiple Over Coming Years

A peer in the same niche gets bought out at a big premium, and some analysts argue it shows the market may be undervaluing Certara despite recent target cuts. Meanwhile, leadership changes and a heavier investment push put the spotlight on whether the company can turn its pipeline into steadier growth.

4 views

Biosimulation Expansion And AI Products Will Drive Long Term Margin Upside

CERT: Peer Deal Premium And Buybacks Will Highlight Depressed Multiple

CERT: Peer Deal Premium Will Highlight Depressed Multiple Over Coming Years

Fair Value vs Share Price

Recent News & Updates

Recent updates

Stay ahead on Certara

Company analysis

CEO & management